利妥昔单抗在 HIV 相关淋巴瘤和多中心 Castleman 病患者中的临床应用。

Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.

机构信息

Moores Cancer Center, University of California, San Diego, USA.

出版信息

Curr Drug Deliv. 2012 Jan;9(1):41-51. doi: 10.2174/156720112798376005.

DOI:10.2174/156720112798376005

PMID:22023215

Abstract

The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDS-related non-Hodgkin lymphoma and Multicentric Castleman's disease.

摘要

免疫疗法在治疗非霍奇金淋巴瘤中的应用提高了该人群的缓解率和生存率。随着利妥昔单抗的广泛应用和接受利妥昔单抗治疗的患者的长期随访，感染并发症正在增加。这些并发症在艾滋病相关淋巴瘤人群中引起了极大的关注。我们回顾了迄今为止利妥昔单抗的活性和感染毒性数据，以及它在治疗艾滋病相关非霍奇金淋巴瘤和多中心Castleman 病中的应用。